Company recalls 67,000 cases of stick deodorant

A.P. Deauville, LLC, has voluntarily recalled more than 67,000 cases of various Power Stick roll-on antiperspirant deodorants nationwide due to deviations from current Good Manufacturing Practice regulations, according to an enforcement report of the Food and Drug Administration.

The recall, initiated by the Easton, Pennsylvania-based firm on July 10, 2025, affects three specific Power Stick products: Power Stick for her roll-on Antiperspirant Deodorant Powder Fresh, Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh, and Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant.

In total, 67,214 cases of antiperspirant are subject to the recall. This includes 21,265 cases of the Powder Fresh variety, 22,482 cases of the Spring Fresh, and 23,467 cases of the Original Nourishing formula. The products were distributed across the country.

The recall, initiated by the Easton, Pennsylvania-based firm on July 10, 2025, specifically targets three Power Stick products, all distributed nationwide:

Power Stick for her roll-on Antiperspirant Deodorant Powder Fresh, 1.8 oz/53 mL (UPC Code 815195019313, NDC# 42913-038-00). This recall affects lot numbers 032026B011, 032226B031, 051626C241, 061526C882, 071226D371, 071226D381, 082526E341, and 082826E402.

Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh, 1.8 oz/53 mL (UPC Code 815195018194, NDC# 42913-039-00). The cases are being recalled, encompassing lot numbers 031726A991, 041226B561, 062026C901, 062026C911, 071026D351, 071026D361, 071326D391, and 111626G231.

Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant, 1.8 oz/ 53 mL (UPC Code 815195018224, NDC# 42913-040-00). This recall impacts products with lot numbers 101225D781, 032926B281, 032826B221, 041126B531, 062226D011, 070626D301, 070626D333, 111026G051, 111326G091, and 111626G221.

The reason for the recall is listed as "cGMP deviations," indicating that the products were not manufactured under conditions that comply with the FDA's current Good Manufacturing Practice regulations. These regulations ensure that drug products meet quality standards for identity, strength, quality, and purity.

The FDA notes that a drug manufactured in violation of cGMP is considered "adulterated" under the law, though it does not necessarily mean there is something inherently wrong with the drug itself. Consumers are generally advised by the FDA not to interrupt their drug therapy without consulting a healthcare professional.

21 News has emailed A.P. Deauville, LLC, for more information. As of this writing the company has yet to respond.